The bleeding disorder-specific corporate reputation results are in, and Sobi has landed the top spot.
That’s according to PatientView’s annual corporate reputation survey (PDF) for 2025/2026, which drew its results after polling 65 bleeding disorder patient groups across 31 countries between December 2025 and March 2026. Respondents were asked to weigh nine bleeding disorder companies across several different factors to determine which have the highest reputation between Bayer, BioMarin, CSL Behring, Novo Nordisk, Pfizer, Sanofi, Sobi, Takeda and Roche and its subsidiaries Genentech and Chugai Pharmaceutical.
The top three showed no difference between the two categories PatientView uses to differentiate companies that respondents have worked with firsthand or companies that respondents are familiar with. For both categories, Sobi topped the list at No. 1, while Roche/Genentech/Chugai came in second and Novo took third.
Although they didn’t make the top three this year, two companies still notably climbed the ranks in Sanofi and CSL Behring. Sanofi took the crown for the fastest-rising company in the group of drugmakers respondents were familiar with, zooming up two places from its last ranking. CSL Behring, meanwhile, jumped up a spot when ranked by respondents who have experience working with the company.
The bleeding disorder patient groups, which together supported 204,000 patients over the last year, made their picks based on a wide set of indicators of corporate reputation, including safety, pricing transparency, equitable access and integrity. Over the past five years since PatientView’s 2021/2022 survey, the patient groups view of the corporate reputation of the pharma industry as a whole has declined.
Specific areas in which the industry weakened over that timeframe, according to the respondents, lay in access to medicines, services ‘beyond the pill’, patient engagement in R&D and the provision of patient information. However, the patient groups also reported boosts in transparency in clinical data, innovation ability, commitment to patient safety and more, while “slight” increases were perceived in fair pricing policies, price transparency and products of benefit to patients with bleeding disorders.
“Our needs regarding our entire population have not been met yet, although we have preventative treatment for all patients through the Unified Health System/SUS [Sistema Único de Saúde, the National Health System of Brazil],” one bleeding disorders patient group out of Brazil commented in PatientView’s press release.
Sobi and Roche’s corporate reputations have earned high marks as of late, with Sobi nabbing the top spot for overall corporate reputation in rare disease in 2024. In that report, Roche took second place under Sobi as ranked by 518 rare disease patient groups. Roche also claimed the No. 1 spot when it comes to cancer rankings in a recent PatientView report released last week.
Swedish pharma Sobi’s biggest drug sector is hematology, where it markets a number of bleeding disorder drugs including Sanofi-partnered Altuviiio and Eloctate, both of which treat hemophilia A. Roche, for its part, sells hemophilia A mainstay Hemlibra, which remains a top growth driver for the company.